Filing Details
- Accession Number:
- 0000874015-15-000033
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-02-17 17:39:14
- Reporting Period:
- 2015-02-12
- Filing Date:
- 2015-02-17
- Accepted Time:
- 2015-02-17 17:39:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874015 | Isis Pharmaceuticals Inc | ISIS | Pharmaceutical Preparations (2834) | 330336973 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1073384 | H Joseph Wender | C/O Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad CA 92010 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-02-12 | 10,000 | $3.95 | 47,217 | No | 4 | M | Indirect | By Trust |
Common Stock | Disposition | 2015-02-12 | 10,000 | $62.15 | 37,217 | No | 4 | S | Indirect | By Trust |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Indirect | By Trust |
No | 4 | S | Indirect | By Trust |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Employee Director Stock Option (right to buy) | Disposition | 2015-02-12 | 10,000 | $0.00 | 10,000 | $3.95 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2009-07-01 | 2015-06-30 | No | 4 | M | Indirect |
Footnotes
- Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2015.
- The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.960 to $62.325, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.